Maia Biotechnology Inc (MAIA) Stock AnalysisMAIAStock AnalysisMaia Biotechnology Inc

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine), is a lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Maia Biotechnology Inc is not a good buy right now due to its negative earnings and weak technical indicators. The current price is $1.33, with an RSI of 35.61 indicating oversold conditions. Furthermore, the company has reported consistent net losses, with a net income of -7943587 USD in Q2 2026, and a forward P/E ratio of 0, suggesting no earnings growth expectations. The main risk is the potential for further declines in stock price, as indicated by a 5-day change of -4.32%.